Structure-activity relationships of azasugar-based MMP/ADAM inhibitors

被引：16

作者：

Moriyama, H

Tsukida, T

Inoue, Y

Kondo, H

Yoshino, K

Nishimura, SI

机构：

[1] Japan Bioind Assoc, Hokkaido Collaborat Ctr, Kita Ku, Sapporo, Hokkaido 0010021, Japan

[2] Nippon Organon KK, R&D Labs, Miyakojima Ku, Osaka 5340016, Japan

[3] Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0010021, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 16期

关键词：

D O I：

10.1016/S0960-894X(03)00530-4

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In order to investigate structure-activity relationships of azasugar series toward metalloprotemases, we synthesized and evaluated several azasugar-based compounds. As a result, it was found that 4-phenoxybenzene derivative 3 having 2R,3R,4R,5S-configurations exhibited most potent inhibitory activities against matrix metalloproteinase-1, -3 and -9 and TACE. (C) 2003 Elsevier Ltd. All rights reserved.

引用

收藏

页码：2737 / 2740

页数：4

相关论文

共 19 条

[1] Matrix metalloproteinase inhibitors 1998 [J].

Beckett, RP ;

Whittaker, M .

EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (03) :259-282

[2]

Bemelmans MHA, 1996, CRIT REV IMMUNOL, V16, P1

[3] ADAMs: focus on the protease domain [J].

Black, RA ;

White, JM .

CURRENT OPINION IN CELL BIOLOGY, 1998, 10 (05) :654-659

[4] Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor [J].

Clements, JM ;

Cossins, JA ;

Wells, GMA ;

Corkill, DJ ;

Helfrich, K ;

Wood, LM ;

Pigott, R ;

Stabler, G ;

Ward, GA ;

Gearing, AJH ;

Miller, KM .

JOURNAL OF NEUROIMMUNOLOGY, 1997, 74 (1-2) :85-94

[5] Chirospecific synthesis of 1,4-dideoxy-1,4-imino-D-arabinitol and 1,4-dideoxy-1,4-imino-L-xylitol via one-pot cyclisation [J].

Kim, JH ;

Yang, MS ;

Lee, WS ;

Park, KH .

JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1998, (17) :2877-2880

[6]

Lee BW, 2000, SYNTHESIS-STUTTGART, P1305

[7]

Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217

[8]

Michaelides MR, 1999, CURR PHARM DESIGN, V5, P787

[9] Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [J].

Moreland, LW ;

Baumgartner, SW ;

Schiff, MH ;

Tindall, EA ;

Fleischmann, RM ;

Weaver, AL ;

Ettlinger, RE ;

Cohen, S ;

Koopman, WJ ;

Mohler, K ;

Widmer, MB ;

Blosch, CM .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :141-147

[10] KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production [J].

Morimoto, Y ;

Nishikawa, K ;

Ohashi, M .

LIFE SCIENCES, 1997, 61 (08) :795-803